(SMHB) ETRACS 2xMonthly Pay - Ratings and Ratios
Leveraged, Returns, Small-Cap, Dividends, Monthly, Compounded, Performance
Description: SMHB ETRACS 2xMonthly Pay
The ETRACS 2xMonthly Pay Leveraged US Small Cap High Dividend ETN (SMHB) is designed to track the performance of 100 small-cap, dividend-yielding US stocks, with a leverage factor of 2. This means that the ETN will amplify both the positive and negative returns of the underlying index, compounded monthly.
The underlying index focuses on relatively small capitalization stocks with a history of paying dividends, providing a unique blend of income generation and potential for capital appreciation. The ETNs leveraged nature makes it sensitive to market fluctuations, and its performance is closely tied to the overall direction of the US small-cap market.
Analyzing the technical data, we observe that the ETNs price is currently below its 20-day and 50-day simple moving averages (SMA20 and SMA50), indicating a short-term downtrend. The 200-day simple moving average (SMA200) is significantly higher, suggesting a longer-term downtrend. The Average True Range (ATR) is 0.20, representing 5.08% of the current price, indicating moderate volatility.
Considering the fundamental data, the ETNs Assets Under Management (AUM) stand at $21.91M, which is relatively small. This could lead to liquidity concerns and potentially impact the ETNs ability to track the underlying index.
Forecasting the ETNs performance, we can expect the leveraged nature to amplify any market movements. Given the current technical downtrend and moderate volatility, we anticipate a continued decline in the short term. However, if the US small-cap market reverses direction, the ETNs leveraged nature could lead to a significant increase in value. To mitigate potential losses, it is essential to closely monitor the ETNs price action and adjust positions accordingly.
Based on the technical and fundamental analysis, a potential trading strategy could involve waiting for a clear reversal signal, such as a break above the SMA20 or SMA50, before entering a long position. Conversely, a short position could be considered if the ETNs price continues to decline, breaking below the 52-week low.
Additional Sources for SMHB ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
SMHB ETF Overview
Market Cap in USD | 26m |
Category | Trading--Leveraged Equity |
TER | 0.85% |
IPO / Inception | 2018-11-08 |
SMHB ETF Ratings
Growth Rating | 8.61 |
Fundamental | - |
Dividend Rating | 56.6 |
Rel. Strength | -11.9 |
Analysts | - |
Fair Price Momentum | 4.79 USD |
Fair Price DCF | - |
SMHB Dividends
Dividend Yield 12m | 18.21% |
Yield on Cost 5y | 40.01% |
Annual Growth 5y | -3.15% |
Payout Consistency | 75.5% |
Payout Ratio | % |
SMHB Growth Ratios
Growth Correlation 3m | 88.6% |
Growth Correlation 12m | -75.9% |
Growth Correlation 5y | -9.5% |
CAGR 5y | 16.66% |
CAGR/Max DD 5y | 0.28 |
Sharpe Ratio 12m | -0.09 |
Alpha | -22.49 |
Beta | 1.017 |
Volatility | 39.85% |
Current Volume | 95.4k |
Average Volume 20d | 28.1k |
Stop Loss | 4.3 (-4.9%) |
As of July 17, 2025, the stock is trading at USD 4.52 with a total of 95,429 shares traded.
Over the past week, the price has changed by -4.67%, over one month by +4.58%, over three months by +29.78% and over the past year by -10.18%.
Neither. Based on ValueRay´s Analyses, ETRACS 2xMonthly Pay is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 8.61 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SMHB is around 4.79 USD . This means that SMHB is currently overvalued and has a potential downside of 5.97%.
ETRACS 2xMonthly Pay has no consensus analysts rating.
According to our own proprietary Forecast Model, SMHB ETRACS 2xMonthly Pay will be worth about 5.6 in July 2026. The stock is currently trading at 4.52. This means that the stock has a potential upside of +23.01%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 5.6 | 23% |